A breakthrough technology developed by Biobank.cy has been selected for the latest round of innovation funding from Cyprus Seeds, a strategic program fostering business development. This pioneering nano-invention, poised to revolutionize the treatment of triple-negative breast cancer (TNBC), has opened new doors for precise, targeted therapy, offering patients a hope for more effective treatments with fewer side effects.
The technology at the heart of this innovation leverages nanotechnology to deliver therapeutic molecules directly into specific cancer cells, leaving healthy cells unharmed. This precision approach enhances the therapeutic impact of treatments while significantly reducing the adverse effects typically caused by chemotherapy. In essence, this new technology has the potential to transform breast cancer treatment, ensuring that patients receive targeted interventions without the unwanted collateral damage of traditional chemotherapy.
Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram
This development is particularly important for TNBC, a rare and aggressive form of breast cancer that accounts for 15-20% of all cases but is notoriously difficult to treat due to a lack of specific biomarkers. With this novel nano-platform, researchers can enhance drug delivery to these challenging cancer cells while minimizing harm to healthy tissues—an approach that can increase treatment efficacy and improve overall patient outcomes.
Expanding Beyond Breast Cancer: New Frontiers In Kidney Disease Treatment
But the innovation doesn’t stop there. The technology, initially designed to address TNBC, is already being adapted by the research team for the treatment of rare kidney diseases. As a versatile nano-platform, this technology is being explored for new drug delivery strategies in nephrology, opening up the potential for breakthrough treatments in a variety of medical conditions.
The research behind this nano-platform is led by Dr. Giota Grigoriou, a senior scientist at Biobank.cy, with the expertise of Dr. Grigoris Papagrigoriou and the full support of Biobank.cy’s Innovation Pillar. The team’s cutting-edge infrastructure and scientific capabilities are integral to the development of these therapeutic advancements.
The Role Of Cyprus Seeds In Advancing Scientific Innovation
Cyprus Seeds, the non-profit organization responsible for this selection, is dedicated to supporting the commercialization of high-potential scientific research emerging from Cypriot universities and research institutions. By providing funding, mentorship, and a global network of investors, Cyprus Seeds helps translate breakthrough discoveries into practical applications, ensuring their global reach.
Maria Markidou Georgiadou, the Managing Director of Cyprus Seeds, praised the project, noting that this is the first time the organization has supported a team from Biobank.cy. Along with crucial financial backing, the team will benefit from expert guidance from mentors in the U.S. and Greece, as well as the opportunity to network with key stakeholders and undergo business training.
Looking Ahead: A Global Health Impact
Professor Constantinos Deltas, Medical and Molecular Genetics specialist and Director of the Biobank.cy Center of Excellence, emphasized the significance of the collaboration with Cyprus Seeds. He believes that this partnership marks a major milestone in their efforts to advance human health, both in Cyprus and globally.
As the world continues to battle cancer and other complex diseases, innovations like these are setting a new precedent in medical treatment—proving that the future of healthcare lies in precision, innovation, and collaboration.
